Compare Li Auto Inc (LI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Li Auto (LI) trades at $11.61, down 5.64% on the day and near 52-week lows amid delivery concerns. The technical picture is bearish with negative moving averages, while fundamentals show revenue declining from $144.5B in 2024 to $112.3B in 2025, though the company maintains a strong balance sheet with $112.8B cash. Recent Q2 2026 earnings missed expectations with a net loss of $0.25 per share, and September deliveries of 31,817 vehicles indicate volume moderation.

The outlook remains challenging with intense EV competition and margin pressure, but analyst consensus suggests 31% upside to the $15.18 price target. Key risks include execution on new model launches (Li i9, MEGA) and China's auto market slowdown, while the company's cash position provides buffer against near-term headwinds.

Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.

REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.